Cost-effectiveness, avoidance of diagnostic delays, low complication rates, and minimal invasiveness are the advantages of tru-cut biopsy. The potential disadvantages are decreased diagnostic accuracy and possible tumor sampling error. The aim of the present study was to evaluate the accuracy of tru-cut biopsy with regard to its diagnostic yield and to investigate the factors associated with the diagnostic outcomes for distinguishing benign and malignant soft tissue tumors.
Methods
This study was approved by the noninvasive ethical committee of Bağcılar Training and Research Hospital (2015/410). The pathology results of 41 patients (21 females) who underwent a tru-cut biopsy using the tru-cut system (Matek Opticore tru-cut biopsy needle, Matek, İstanbul, Turkey) and received subsequent tumor resection at our hospital, Pathology Department from January 2011 to June 2015 were evaluated retrospectively. All biopsies were performed by an experienced radiologist under ultrasonography. All specimens were fixed with 10% neutral-buffered formalin and processed routinely using hematoxylin and eosin stain for permanent and subsequent immunohistochemical studies performed at the discretion of the interpreting pathologist.
The samples were evaluated by a pathologist experienced in the field of orthopedic oncology and soft tissue pathology. Diagnostic biopsies were analyzed for accuracy with regard to the final histopathological diagnosis of the resected tissue. Reactive and inflammatory soft tissue lesion samples were excluded from the analysis. The final diagnosis was made using the histopathological examination of the resected lesions.
Confirmatory histological specimen reports were available from previous tru-cut histological specimens in one patient presenting with soft tissue masses and from definitive surgical resections. The pathological diagnosis was performed according to the WHO 2013 soft tissue tumor classification system (11) . All samples were assessed for the benign or malignant nature of the lesion and for a definite histological diagnosis. Written informed consent was obtained from each patient.
The Statistical Package for Social Sciences software version 22.0 (SPSS Inc.; Chicago, IL, USA) was used for statistical analysis. Trucut biopsy and subsequent resection pathology results from were compared. Sensitivity, specificity, and diagnostic compatibility (Kappa analysis) were calculated. A p value less than 0.05 was accepted as statistically significant.
Results
Thirty-six primary and five secondary soft tissue tumors were evaluated in the study based on final diagnosis. The mean age of the patients was 52.8±16.8 years. Tru-cut biopsy was positive for malignancy in 12 patients. Two patients were diagnosed as gastrointestinal stromal tumor (GIST) according to mitosis, location, and size, whereas one patient was diagnosed as high and the other as an intermediate potential risk after the histopathological evaluation of the resected lesions. Two out of four patients with aggressive fibromatosis were misdiagnosed as benign mesenchymal proliferation through tru-cut biopsy (Figure 1 ). Ten patients had descriptive diagnosis (pieces of lipomatous tissue, connective tissue, skeletal muscle, etc.) through tru-cut biopsy, whereas nine had lipoma and one had xanthoma as the final diagnosis (Figure 2 ). Of these cases, seven were compatible with lipoma because of preoperative radiological evaluation. One case was equivocal for atypical lipoma through radiological evaluation, and the final diagnosis was fibrolipoma. Another case was evaluated as xanthoma through excisional biopsy, but the previous radiological diagnosis was reported as soft tissue tumor. One patient's diagnosis was vascular neoplasia through trucut biopsy, and the final diagnosis was cavernous hemangioma. Two of the primary soft tissue tumors with myxoid features were correctly identified with tru-cut biopsy (Figure 3) . We did not observe any significant complications, such as hematoma, infection, or impaired wound healing following tru-cut biopsy.
The tru-cut biopsy and pathological final diagnosis of the resected tissues showed an 89% (Kappa analysis, p<0.001) correlation excluding the patients with a descriptive tru-cut biopsy diagnosis. The diagnostic sensitivity was 93.3% and the specificity was 90.9% in our study. The distribution of the lesion sites and diagnoses were highly variable. The patient characteristics, results of tru-cut biopsy, and final diagnosis are shown in Table 1 .
Discussion
A tru-cut biopsy helps reveal the tumor structure and cell configuration and is the fundamental step for the diagnosis of soft tissue İstanbul Med J 2018; 19(4): 295-9 tumors. The diagnostic accuracy of tru-cut biopsy has been reported between 69% and 99% (12) . The sensitivity ranges between 82% and 95% with a negative predictive value between 76% and 91% (12, 13). The false negative results or diagnostic inaccuracy may depend upon several factors, such as the lesion type, location, experience of the radiologist, and the pathologist. Each of these factors may have comparable influences on the outcome, and false negative biopsies may deleteriously affect the treatment strategy.
In the present study, the sensitivity was 93.3% and the specificity was 90.9%. These findings correlate well with the recent studies. Cooperation of the orthopedist, radiologist, and pathologist may increase the diagnostic yield of tru-cut biopsy because of sampling error, by identifying the convenient or satisfactory tumor area for biopsy. Besides, tru-cut biopsy is a safe technique with a negligible complication rate ranging from 0% to 7.4% in recent studies (14, 15) . We did not observe any significant complications associated with the tru-cut biopsy procedure in our patients.
The treatment of soft tissue tumors has focused on limb-salvage surgery during the last two decades. This approach has privileges of accurate diagnosis compared to invasive procedures for guiding the treatment options. Mankin et al. (5) demonstrated a complication rate of 17% for open musculoskeletal biopsies. The complication rate increased two-fold when the biopsy was performed outside of a primary musculoskeletal treatment institution (5) . In a multidisciplinary setting of established treating centers for musculoskeletal neoplasms, nondiagnostic tru-cut biopsy and tru-cut biopsy errors can be identified and addressed appropriately without resultant surgical errors (1) . The results of our study indicate that the diagnostic utility of tru-cut biopsy highly depends on the multidisciplinary team work of the radiologist, orthopedic surgeon, and the pathologist.
For malignant lesions where a confirmatory diagnostic tissue and features were unavailable, pathologists used immunohistochemistry to confirm the histopathological interpretation and concordant clinical findings to determine the accuracy of the biopsy diagnosis. The lowest diagnostic accuracy rate was obtained with the needle biopsies for myxoid, infectious, and round cell histology lesions (15, 16 (15) revealed a low diagnostic ratio for myxoid lesions. Various studies have also reported that the tumor subtype is the essential dilemma for the interpretation of tru-cut biopsy specimens (2, 15, 17, 18) . In our study group, two primary soft tissue tumors with myxoid features were identified correctly as malignant because they had high-grade features. Sung et al. (18) reported a low diagnostic yield and accuracy in heterogeneous tumors, such as angiosarcoma, liposarcoma, synovial sarcomas, and hemangiomas. A case was diagnosed only as a vascular neoplasia in our study because fibrinous deposits and thrombi were present in most of the vascular lumen. Tru-cut biopsy was also diagnostic in a hemangioendothelioma case. As a result, the total excision specimen should be imperative for an adequate identification of the malignancy potential for vascular neoplasia. Mitsuyoshi et al. (17) reported difficulties in differentiating low-grade liposarcoma from benign lipoma. In our study, a descriptive diagnosis was reported for nine cases of benign lipomatous tumors because of the fragments representing the lesion and the surrounding tissues. Consequently, a radiological evaluation appeared imperative as the initial step for the diagnosis of lipomatous tumors. In contrast, lack of atypical histological features supported the benign diagnosis. Malignant and atypical lipomatous tumors were correctly diagnosed using tru-cut biopsy. Three of these cases were well-differentiated liposarcomas and were diagnosed as atypical lipomatous tumor through tru-cut biopsy. A dedifferentiated liposarcoma had been diagnosed as malignant mesenchymal tumor by tru-cut biopsy. Well-differentiated liposarcomas can be diagnosed using tru-cut biopsy with regard to the presence of atypical cellular features, whereas other high-grade malignant mesenchymal tumors should be included in the differential diagnosis of high-grade liposarcomas.
Multiple factors may affect the quality of the guided tru-cut biopsy. Some of these may be lesion specific, such as the tumor type, size, and location, whereas others may be technical in nature, such as the needle size, needle diameter, experience of the clinician, number, and size of the acquired tissue specimens (16) . It is well known that as tumors enlarge they may outgrow their blood supply, leading to necrotic areas within the tumor. Sampling of such necrotic areas may lead to inadequate biopsy specimens. The best biopsy samples are typically localized at the margins of the tumor because of the poor diagnostic quality of central tumor mass. One of the secondary soft tissue tumors was diagnosed as a myxoid spindle cell neoplasm, but the final diagnosis of the resected tumor was an adenocarcinoma metastasis ( Figure 4 ). This erroneous diagnosis was because of the sampling of the reactive zone in the peripheral tumor area by tru-cut biopsy. Besides, metastatic tumors are the most frequent secondary soft tissue tumors as it is in our study. These usually may simulate primary soft tissue tumors both clinically and radiologically.
The essential point for a successful tru-cut biopsy in the diagnosis of soft tissue lesions depends upon a careful algorithmic procedure planning by an experienced orthopedic surgeon or a well-trained interventional radiologist in this field with respect to the suspected lesion, extent of necrosis, and the location for avoiding erroneous results or inadequate biopsy specimens (3). Besides its diagnostic facility, tru-cut biopsy is also useful for the treatment strategy including the surgical approach and the neo-adjuvant chemotherapy. The complication rate is even less than 5% when performed by (5, 19) . The most frequent complications are hematoma, bleeding, and infection of the biopsy site. We have not observed any of these complications in our patients.
The limitation of the present study is the small sample size. Further studies with larger populations and heterogeneous tumors are needed to identify the real diagnostic utility of the tru-cut biopsy. Tru-cut biopsy usually allows a definitive diagnosis and is useful for further treatment strategy options, but its limitations must also be recognized. Clinicians should be aware of the uncertainties of this technique when descriptive diagnosis or nonspecific tissue specimens are reported (20) . Our diagnostic criteria fundamentally depend upon the histomorphological, clinical, and radiological features. Because of the presence of heterogeneous features of the soft tissue tumors and particularly the small size of the biopsy samples, diagnosis of such lesions are reported in large category groups, such as malignant myxoid neoplasm or spindle cell malignant tumor. For the evaluation of heterogeneous areas, multiple biopsy samples are needed for tru-cut biopsy. We were unable to perform genetic studies for these patients because we did not have a molecular pathology laboratory. Immunohistochemical staining was used for the differential diagnosis of these lesions.
Conclusion
Although the sample size was small, tru-cut biopsy for diagnosing in soft tissue tumors proved to be a safe and efficient procedure. The diagnostic accuracy of tru-cut biopsy is high. If the procedure is not diagnostic at the initial step, it is useful for leading the clinician in the correct path for the further diagnostic work-up of the patient. Advantages are low cost, avoidance of diagnostic delay, low complication rates, and the small incisions compared to surgical open biopsy. In contrast, decreased diagnostic accuracy because of possible tumor sampling error and tumor heterogeneity may be considered a disadvantage.
Microscopic features of low-grade and well-differentiated tumors, which have an initial descriptive diagnosis by tru-cut biopsy, should be evaluated with preoperative radiological assessment. In high-grade malignant mesenchymal tumors, the biopsy may not reveal the specific type but is useful by identifying the malignant tumors, thereby leading to a correct treatment plan.
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